Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
7,533
archived clinical trials in
Chronic Obstructive Pulmonary Disease

Chronic Obstructive Pulmonary Disease (COPD) Post-hospitalization Study
A Randomized, Double-Blind, Parallel Group, Multicenter Study of the Effects of Fluticasone Propionate/Salmeterol Combination Product 250/50mcg BID (ADVAIR DISKUS™) in Comparison to Salmeterol 50mcg BID (SEREVENT DISKUS™) on the Rate of Exacerbations of COPD Following Hospitalization
Status: Enrolling
Updated:  10/9/2017
GSK Investigational Site
mi
from
Portland, OR
Chronic Obstructive Pulmonary Disease (COPD) Post-hospitalization Study
A Randomized, Double-Blind, Parallel Group, Multicenter Study of the Effects of Fluticasone Propionate/Salmeterol Combination Product 250/50mcg BID (ADVAIR DISKUS™) in Comparison to Salmeterol 50mcg BID (SEREVENT DISKUS™) on the Rate of Exacerbations of COPD Following Hospitalization
Status: Enrolling
Updated: 10/9/2017
GSK Investigational Site
mi
from
Portland, OR
Click here to add this to my saved trials
Chronic Obstructive Pulmonary Disease (COPD) Post-hospitalization Study
A Randomized, Double-Blind, Parallel Group, Multicenter Study of the Effects of Fluticasone Propionate/Salmeterol Combination Product 250/50mcg BID (ADVAIR DISKUS™) in Comparison to Salmeterol 50mcg BID (SEREVENT DISKUS™) on the Rate of Exacerbations of COPD Following Hospitalization
Status: Enrolling
Updated:  10/9/2017
GSK Investigational Site
mi
from
Pittsburgh, PA
Chronic Obstructive Pulmonary Disease (COPD) Post-hospitalization Study
A Randomized, Double-Blind, Parallel Group, Multicenter Study of the Effects of Fluticasone Propionate/Salmeterol Combination Product 250/50mcg BID (ADVAIR DISKUS™) in Comparison to Salmeterol 50mcg BID (SEREVENT DISKUS™) on the Rate of Exacerbations of COPD Following Hospitalization
Status: Enrolling
Updated: 10/9/2017
GSK Investigational Site
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Chronic Obstructive Pulmonary Disease (COPD) Post-hospitalization Study
A Randomized, Double-Blind, Parallel Group, Multicenter Study of the Effects of Fluticasone Propionate/Salmeterol Combination Product 250/50mcg BID (ADVAIR DISKUS™) in Comparison to Salmeterol 50mcg BID (SEREVENT DISKUS™) on the Rate of Exacerbations of COPD Following Hospitalization
Status: Enrolling
Updated:  10/9/2017
GSK Investigational Site
mi
from
Easley, SC
Chronic Obstructive Pulmonary Disease (COPD) Post-hospitalization Study
A Randomized, Double-Blind, Parallel Group, Multicenter Study of the Effects of Fluticasone Propionate/Salmeterol Combination Product 250/50mcg BID (ADVAIR DISKUS™) in Comparison to Salmeterol 50mcg BID (SEREVENT DISKUS™) on the Rate of Exacerbations of COPD Following Hospitalization
Status: Enrolling
Updated: 10/9/2017
GSK Investigational Site
mi
from
Easley, SC
Click here to add this to my saved trials
Chronic Obstructive Pulmonary Disease (COPD) Post-hospitalization Study
A Randomized, Double-Blind, Parallel Group, Multicenter Study of the Effects of Fluticasone Propionate/Salmeterol Combination Product 250/50mcg BID (ADVAIR DISKUS™) in Comparison to Salmeterol 50mcg BID (SEREVENT DISKUS™) on the Rate of Exacerbations of COPD Following Hospitalization
Status: Enrolling
Updated:  10/9/2017
GSK Investigational Site
mi
from
Fort Mill, SC
Chronic Obstructive Pulmonary Disease (COPD) Post-hospitalization Study
A Randomized, Double-Blind, Parallel Group, Multicenter Study of the Effects of Fluticasone Propionate/Salmeterol Combination Product 250/50mcg BID (ADVAIR DISKUS™) in Comparison to Salmeterol 50mcg BID (SEREVENT DISKUS™) on the Rate of Exacerbations of COPD Following Hospitalization
Status: Enrolling
Updated: 10/9/2017
GSK Investigational Site
mi
from
Fort Mill, SC
Click here to add this to my saved trials
Chronic Obstructive Pulmonary Disease (COPD) Post-hospitalization Study
A Randomized, Double-Blind, Parallel Group, Multicenter Study of the Effects of Fluticasone Propionate/Salmeterol Combination Product 250/50mcg BID (ADVAIR DISKUS™) in Comparison to Salmeterol 50mcg BID (SEREVENT DISKUS™) on the Rate of Exacerbations of COPD Following Hospitalization
Status: Enrolling
Updated:  10/9/2017
GSK Investigational Site
mi
from
Gaffney, SC
Chronic Obstructive Pulmonary Disease (COPD) Post-hospitalization Study
A Randomized, Double-Blind, Parallel Group, Multicenter Study of the Effects of Fluticasone Propionate/Salmeterol Combination Product 250/50mcg BID (ADVAIR DISKUS™) in Comparison to Salmeterol 50mcg BID (SEREVENT DISKUS™) on the Rate of Exacerbations of COPD Following Hospitalization
Status: Enrolling
Updated: 10/9/2017
GSK Investigational Site
mi
from
Gaffney, SC
Click here to add this to my saved trials
Chronic Obstructive Pulmonary Disease (COPD) Post-hospitalization Study
A Randomized, Double-Blind, Parallel Group, Multicenter Study of the Effects of Fluticasone Propionate/Salmeterol Combination Product 250/50mcg BID (ADVAIR DISKUS™) in Comparison to Salmeterol 50mcg BID (SEREVENT DISKUS™) on the Rate of Exacerbations of COPD Following Hospitalization
Status: Enrolling
Updated:  10/9/2017
GSK Investigational Site
mi
from
Greenville, SC
Chronic Obstructive Pulmonary Disease (COPD) Post-hospitalization Study
A Randomized, Double-Blind, Parallel Group, Multicenter Study of the Effects of Fluticasone Propionate/Salmeterol Combination Product 250/50mcg BID (ADVAIR DISKUS™) in Comparison to Salmeterol 50mcg BID (SEREVENT DISKUS™) on the Rate of Exacerbations of COPD Following Hospitalization
Status: Enrolling
Updated: 10/9/2017
GSK Investigational Site
mi
from
Greenville, SC
Click here to add this to my saved trials
Chronic Obstructive Pulmonary Disease (COPD) Post-hospitalization Study
A Randomized, Double-Blind, Parallel Group, Multicenter Study of the Effects of Fluticasone Propionate/Salmeterol Combination Product 250/50mcg BID (ADVAIR DISKUS™) in Comparison to Salmeterol 50mcg BID (SEREVENT DISKUS™) on the Rate of Exacerbations of COPD Following Hospitalization
Status: Enrolling
Updated:  10/9/2017
GSK Investigational Site
mi
from
Seneca, SC
Chronic Obstructive Pulmonary Disease (COPD) Post-hospitalization Study
A Randomized, Double-Blind, Parallel Group, Multicenter Study of the Effects of Fluticasone Propionate/Salmeterol Combination Product 250/50mcg BID (ADVAIR DISKUS™) in Comparison to Salmeterol 50mcg BID (SEREVENT DISKUS™) on the Rate of Exacerbations of COPD Following Hospitalization
Status: Enrolling
Updated: 10/9/2017
GSK Investigational Site
mi
from
Seneca, SC
Click here to add this to my saved trials
Chronic Obstructive Pulmonary Disease (COPD) Post-hospitalization Study
A Randomized, Double-Blind, Parallel Group, Multicenter Study of the Effects of Fluticasone Propionate/Salmeterol Combination Product 250/50mcg BID (ADVAIR DISKUS™) in Comparison to Salmeterol 50mcg BID (SEREVENT DISKUS™) on the Rate of Exacerbations of COPD Following Hospitalization
Status: Enrolling
Updated:  10/9/2017
GSK Investigational Site
mi
from
Spartanburg, SC
Chronic Obstructive Pulmonary Disease (COPD) Post-hospitalization Study
A Randomized, Double-Blind, Parallel Group, Multicenter Study of the Effects of Fluticasone Propionate/Salmeterol Combination Product 250/50mcg BID (ADVAIR DISKUS™) in Comparison to Salmeterol 50mcg BID (SEREVENT DISKUS™) on the Rate of Exacerbations of COPD Following Hospitalization
Status: Enrolling
Updated: 10/9/2017
GSK Investigational Site
mi
from
Spartanburg, SC
Click here to add this to my saved trials
Chronic Obstructive Pulmonary Disease (COPD) Post-hospitalization Study
A Randomized, Double-Blind, Parallel Group, Multicenter Study of the Effects of Fluticasone Propionate/Salmeterol Combination Product 250/50mcg BID (ADVAIR DISKUS™) in Comparison to Salmeterol 50mcg BID (SEREVENT DISKUS™) on the Rate of Exacerbations of COPD Following Hospitalization
Status: Enrolling
Updated:  10/9/2017
GSK Investigational Site
mi
from
Union, SC
Chronic Obstructive Pulmonary Disease (COPD) Post-hospitalization Study
A Randomized, Double-Blind, Parallel Group, Multicenter Study of the Effects of Fluticasone Propionate/Salmeterol Combination Product 250/50mcg BID (ADVAIR DISKUS™) in Comparison to Salmeterol 50mcg BID (SEREVENT DISKUS™) on the Rate of Exacerbations of COPD Following Hospitalization
Status: Enrolling
Updated: 10/9/2017
GSK Investigational Site
mi
from
Union, SC
Click here to add this to my saved trials
Chronic Obstructive Pulmonary Disease (COPD) Post-hospitalization Study
A Randomized, Double-Blind, Parallel Group, Multicenter Study of the Effects of Fluticasone Propionate/Salmeterol Combination Product 250/50mcg BID (ADVAIR DISKUS™) in Comparison to Salmeterol 50mcg BID (SEREVENT DISKUS™) on the Rate of Exacerbations of COPD Following Hospitalization
Status: Enrolling
Updated:  10/9/2017
GSK Investigational Site
mi
from
Corsicana, TX
Chronic Obstructive Pulmonary Disease (COPD) Post-hospitalization Study
A Randomized, Double-Blind, Parallel Group, Multicenter Study of the Effects of Fluticasone Propionate/Salmeterol Combination Product 250/50mcg BID (ADVAIR DISKUS™) in Comparison to Salmeterol 50mcg BID (SEREVENT DISKUS™) on the Rate of Exacerbations of COPD Following Hospitalization
Status: Enrolling
Updated: 10/9/2017
GSK Investigational Site
mi
from
Corsicana, TX
Click here to add this to my saved trials
Chronic Obstructive Pulmonary Disease (COPD) Post-hospitalization Study
A Randomized, Double-Blind, Parallel Group, Multicenter Study of the Effects of Fluticasone Propionate/Salmeterol Combination Product 250/50mcg BID (ADVAIR DISKUS™) in Comparison to Salmeterol 50mcg BID (SEREVENT DISKUS™) on the Rate of Exacerbations of COPD Following Hospitalization
Status: Enrolling
Updated:  10/9/2017
GSK Investigational Site
mi
from
Dallas, TX
Chronic Obstructive Pulmonary Disease (COPD) Post-hospitalization Study
A Randomized, Double-Blind, Parallel Group, Multicenter Study of the Effects of Fluticasone Propionate/Salmeterol Combination Product 250/50mcg BID (ADVAIR DISKUS™) in Comparison to Salmeterol 50mcg BID (SEREVENT DISKUS™) on the Rate of Exacerbations of COPD Following Hospitalization
Status: Enrolling
Updated: 10/9/2017
GSK Investigational Site
mi
from
Dallas, TX
Click here to add this to my saved trials
Chronic Obstructive Pulmonary Disease (COPD) Post-hospitalization Study
A Randomized, Double-Blind, Parallel Group, Multicenter Study of the Effects of Fluticasone Propionate/Salmeterol Combination Product 250/50mcg BID (ADVAIR DISKUS™) in Comparison to Salmeterol 50mcg BID (SEREVENT DISKUS™) on the Rate of Exacerbations of COPD Following Hospitalization
Status: Enrolling
Updated:  10/9/2017
GSK Investigational Site
mi
from
Houston, TX
Chronic Obstructive Pulmonary Disease (COPD) Post-hospitalization Study
A Randomized, Double-Blind, Parallel Group, Multicenter Study of the Effects of Fluticasone Propionate/Salmeterol Combination Product 250/50mcg BID (ADVAIR DISKUS™) in Comparison to Salmeterol 50mcg BID (SEREVENT DISKUS™) on the Rate of Exacerbations of COPD Following Hospitalization
Status: Enrolling
Updated: 10/9/2017
GSK Investigational Site
mi
from
Houston, TX
Click here to add this to my saved trials
Chronic Obstructive Pulmonary Disease (COPD) Post-hospitalization Study
A Randomized, Double-Blind, Parallel Group, Multicenter Study of the Effects of Fluticasone Propionate/Salmeterol Combination Product 250/50mcg BID (ADVAIR DISKUS™) in Comparison to Salmeterol 50mcg BID (SEREVENT DISKUS™) on the Rate of Exacerbations of COPD Following Hospitalization
Status: Enrolling
Updated:  10/9/2017
GSK Investigational Site
mi
from
Abingdon, VA
Chronic Obstructive Pulmonary Disease (COPD) Post-hospitalization Study
A Randomized, Double-Blind, Parallel Group, Multicenter Study of the Effects of Fluticasone Propionate/Salmeterol Combination Product 250/50mcg BID (ADVAIR DISKUS™) in Comparison to Salmeterol 50mcg BID (SEREVENT DISKUS™) on the Rate of Exacerbations of COPD Following Hospitalization
Status: Enrolling
Updated: 10/9/2017
GSK Investigational Site
mi
from
Abingdon, VA
Click here to add this to my saved trials
Chronic Obstructive Pulmonary Disease (COPD) Post-hospitalization Study
A Randomized, Double-Blind, Parallel Group, Multicenter Study of the Effects of Fluticasone Propionate/Salmeterol Combination Product 250/50mcg BID (ADVAIR DISKUS™) in Comparison to Salmeterol 50mcg BID (SEREVENT DISKUS™) on the Rate of Exacerbations of COPD Following Hospitalization
Status: Enrolling
Updated:  10/9/2017
GSK Investigational Site
mi
from
Fairfax, VA
Chronic Obstructive Pulmonary Disease (COPD) Post-hospitalization Study
A Randomized, Double-Blind, Parallel Group, Multicenter Study of the Effects of Fluticasone Propionate/Salmeterol Combination Product 250/50mcg BID (ADVAIR DISKUS™) in Comparison to Salmeterol 50mcg BID (SEREVENT DISKUS™) on the Rate of Exacerbations of COPD Following Hospitalization
Status: Enrolling
Updated: 10/9/2017
GSK Investigational Site
mi
from
Fairfax, VA
Click here to add this to my saved trials
Chronic Obstructive Pulmonary Disease (COPD) Post-hospitalization Study
A Randomized, Double-Blind, Parallel Group, Multicenter Study of the Effects of Fluticasone Propionate/Salmeterol Combination Product 250/50mcg BID (ADVAIR DISKUS™) in Comparison to Salmeterol 50mcg BID (SEREVENT DISKUS™) on the Rate of Exacerbations of COPD Following Hospitalization
Status: Enrolling
Updated:  10/9/2017
GSK Investigational Site
mi
from
Spokane, WA
Chronic Obstructive Pulmonary Disease (COPD) Post-hospitalization Study
A Randomized, Double-Blind, Parallel Group, Multicenter Study of the Effects of Fluticasone Propionate/Salmeterol Combination Product 250/50mcg BID (ADVAIR DISKUS™) in Comparison to Salmeterol 50mcg BID (SEREVENT DISKUS™) on the Rate of Exacerbations of COPD Following Hospitalization
Status: Enrolling
Updated: 10/9/2017
GSK Investigational Site
mi
from
Spokane, WA
Click here to add this to my saved trials
Chronic Obstructive Pulmonary Disease (COPD) Post-hospitalization Study
A Randomized, Double-Blind, Parallel Group, Multicenter Study of the Effects of Fluticasone Propionate/Salmeterol Combination Product 250/50mcg BID (ADVAIR DISKUS™) in Comparison to Salmeterol 50mcg BID (SEREVENT DISKUS™) on the Rate of Exacerbations of COPD Following Hospitalization
Status: Enrolling
Updated:  10/9/2017
GSK Investigational Site
mi
from
Bahía Blanca,
Chronic Obstructive Pulmonary Disease (COPD) Post-hospitalization Study
A Randomized, Double-Blind, Parallel Group, Multicenter Study of the Effects of Fluticasone Propionate/Salmeterol Combination Product 250/50mcg BID (ADVAIR DISKUS™) in Comparison to Salmeterol 50mcg BID (SEREVENT DISKUS™) on the Rate of Exacerbations of COPD Following Hospitalization
Status: Enrolling
Updated: 10/9/2017
GSK Investigational Site
mi
from
Bahía Blanca,
Click here to add this to my saved trials
Fluticasone Propionate/Salmeterol Combination 250/50 DISKUS in the Exercise Endurance Time in Patients With Chronic Obstructive Pulmonary Disease
A Study of Fluticasone Propionate/Salmeterol DISKUS Combination Product 250/50 mcg Twice Daily Plus Tiotropium 18 mcg Daily Versus Placebo DISKUS Twice Daily Plus Tiotropium 18 mcg Daily on Exercise Time and Physiological Parameters in Subjects With Chronic Obstructive Pulmonary Disease
Status: Enrolling
Updated:  10/9/2017
GSK Investigational Site
mi
from
Richmond, VA
Fluticasone Propionate/Salmeterol Combination 250/50 DISKUS in the Exercise Endurance Time in Patients With Chronic Obstructive Pulmonary Disease
A Study of Fluticasone Propionate/Salmeterol DISKUS Combination Product 250/50 mcg Twice Daily Plus Tiotropium 18 mcg Daily Versus Placebo DISKUS Twice Daily Plus Tiotropium 18 mcg Daily on Exercise Time and Physiological Parameters in Subjects With Chronic Obstructive Pulmonary Disease
Status: Enrolling
Updated: 10/9/2017
GSK Investigational Site
mi
from
Richmond, VA
Click here to add this to my saved trials
Fluticasone Propionate/Salmeterol Combination 250/50 DISKUS in the Exercise Endurance Time in Patients With Chronic Obstructive Pulmonary Disease
A Study of Fluticasone Propionate/Salmeterol DISKUS Combination Product 250/50 mcg Twice Daily Plus Tiotropium 18 mcg Daily Versus Placebo DISKUS Twice Daily Plus Tiotropium 18 mcg Daily on Exercise Time and Physiological Parameters in Subjects With Chronic Obstructive Pulmonary Disease
Status: Enrolling
Updated:  10/9/2017
GSK Investigational Site
mi
from
Birmingham, AL
Fluticasone Propionate/Salmeterol Combination 250/50 DISKUS in the Exercise Endurance Time in Patients With Chronic Obstructive Pulmonary Disease
A Study of Fluticasone Propionate/Salmeterol DISKUS Combination Product 250/50 mcg Twice Daily Plus Tiotropium 18 mcg Daily Versus Placebo DISKUS Twice Daily Plus Tiotropium 18 mcg Daily on Exercise Time and Physiological Parameters in Subjects With Chronic Obstructive Pulmonary Disease
Status: Enrolling
Updated: 10/9/2017
GSK Investigational Site
mi
from
Birmingham, AL
Click here to add this to my saved trials
Fluticasone Propionate/Salmeterol Combination 250/50 DISKUS in the Exercise Endurance Time in Patients With Chronic Obstructive Pulmonary Disease
A Study of Fluticasone Propionate/Salmeterol DISKUS Combination Product 250/50 mcg Twice Daily Plus Tiotropium 18 mcg Daily Versus Placebo DISKUS Twice Daily Plus Tiotropium 18 mcg Daily on Exercise Time and Physiological Parameters in Subjects With Chronic Obstructive Pulmonary Disease
Status: Enrolling
Updated:  10/9/2017
GSK Investigational Site
mi
from
Phoenix, AZ
Fluticasone Propionate/Salmeterol Combination 250/50 DISKUS in the Exercise Endurance Time in Patients With Chronic Obstructive Pulmonary Disease
A Study of Fluticasone Propionate/Salmeterol DISKUS Combination Product 250/50 mcg Twice Daily Plus Tiotropium 18 mcg Daily Versus Placebo DISKUS Twice Daily Plus Tiotropium 18 mcg Daily on Exercise Time and Physiological Parameters in Subjects With Chronic Obstructive Pulmonary Disease
Status: Enrolling
Updated: 10/9/2017
GSK Investigational Site
mi
from
Phoenix, AZ
Click here to add this to my saved trials
Fluticasone Propionate/Salmeterol Combination 250/50 DISKUS in the Exercise Endurance Time in Patients With Chronic Obstructive Pulmonary Disease
A Study of Fluticasone Propionate/Salmeterol DISKUS Combination Product 250/50 mcg Twice Daily Plus Tiotropium 18 mcg Daily Versus Placebo DISKUS Twice Daily Plus Tiotropium 18 mcg Daily on Exercise Time and Physiological Parameters in Subjects With Chronic Obstructive Pulmonary Disease
Status: Enrolling
Updated:  10/9/2017
GSK Investigational Site
mi
from
Torrance, CA
Fluticasone Propionate/Salmeterol Combination 250/50 DISKUS in the Exercise Endurance Time in Patients With Chronic Obstructive Pulmonary Disease
A Study of Fluticasone Propionate/Salmeterol DISKUS Combination Product 250/50 mcg Twice Daily Plus Tiotropium 18 mcg Daily Versus Placebo DISKUS Twice Daily Plus Tiotropium 18 mcg Daily on Exercise Time and Physiological Parameters in Subjects With Chronic Obstructive Pulmonary Disease
Status: Enrolling
Updated: 10/9/2017
GSK Investigational Site
mi
from
Torrance, CA
Click here to add this to my saved trials
Fluticasone Propionate/Salmeterol Combination 250/50 DISKUS in the Exercise Endurance Time in Patients With Chronic Obstructive Pulmonary Disease
A Study of Fluticasone Propionate/Salmeterol DISKUS Combination Product 250/50 mcg Twice Daily Plus Tiotropium 18 mcg Daily Versus Placebo DISKUS Twice Daily Plus Tiotropium 18 mcg Daily on Exercise Time and Physiological Parameters in Subjects With Chronic Obstructive Pulmonary Disease
Status: Enrolling
Updated:  10/9/2017
GSK Investigational Site
mi
from
Fort Collins, CO
Fluticasone Propionate/Salmeterol Combination 250/50 DISKUS in the Exercise Endurance Time in Patients With Chronic Obstructive Pulmonary Disease
A Study of Fluticasone Propionate/Salmeterol DISKUS Combination Product 250/50 mcg Twice Daily Plus Tiotropium 18 mcg Daily Versus Placebo DISKUS Twice Daily Plus Tiotropium 18 mcg Daily on Exercise Time and Physiological Parameters in Subjects With Chronic Obstructive Pulmonary Disease
Status: Enrolling
Updated: 10/9/2017
GSK Investigational Site
mi
from
Fort Collins, CO
Click here to add this to my saved trials
Fluticasone Propionate/Salmeterol Combination 250/50 DISKUS in the Exercise Endurance Time in Patients With Chronic Obstructive Pulmonary Disease
A Study of Fluticasone Propionate/Salmeterol DISKUS Combination Product 250/50 mcg Twice Daily Plus Tiotropium 18 mcg Daily Versus Placebo DISKUS Twice Daily Plus Tiotropium 18 mcg Daily on Exercise Time and Physiological Parameters in Subjects With Chronic Obstructive Pulmonary Disease
Status: Enrolling
Updated:  10/9/2017
GSK Investigational Site
mi
from
Hartford, CT
Fluticasone Propionate/Salmeterol Combination 250/50 DISKUS in the Exercise Endurance Time in Patients With Chronic Obstructive Pulmonary Disease
A Study of Fluticasone Propionate/Salmeterol DISKUS Combination Product 250/50 mcg Twice Daily Plus Tiotropium 18 mcg Daily Versus Placebo DISKUS Twice Daily Plus Tiotropium 18 mcg Daily on Exercise Time and Physiological Parameters in Subjects With Chronic Obstructive Pulmonary Disease
Status: Enrolling
Updated: 10/9/2017
GSK Investigational Site
mi
from
Hartford, CT
Click here to add this to my saved trials
Fluticasone Propionate/Salmeterol Combination 250/50 DISKUS in the Exercise Endurance Time in Patients With Chronic Obstructive Pulmonary Disease
A Study of Fluticasone Propionate/Salmeterol DISKUS Combination Product 250/50 mcg Twice Daily Plus Tiotropium 18 mcg Daily Versus Placebo DISKUS Twice Daily Plus Tiotropium 18 mcg Daily on Exercise Time and Physiological Parameters in Subjects With Chronic Obstructive Pulmonary Disease
Status: Enrolling
Updated:  10/9/2017
GSK Investigational Site
mi
from
Saint Charles, MO
Fluticasone Propionate/Salmeterol Combination 250/50 DISKUS in the Exercise Endurance Time in Patients With Chronic Obstructive Pulmonary Disease
A Study of Fluticasone Propionate/Salmeterol DISKUS Combination Product 250/50 mcg Twice Daily Plus Tiotropium 18 mcg Daily Versus Placebo DISKUS Twice Daily Plus Tiotropium 18 mcg Daily on Exercise Time and Physiological Parameters in Subjects With Chronic Obstructive Pulmonary Disease
Status: Enrolling
Updated: 10/9/2017
GSK Investigational Site
mi
from
Saint Charles, MO
Click here to add this to my saved trials
Fluticasone Propionate/Salmeterol Combination 250/50 DISKUS in the Exercise Endurance Time in Patients With Chronic Obstructive Pulmonary Disease
A Study of Fluticasone Propionate/Salmeterol DISKUS Combination Product 250/50 mcg Twice Daily Plus Tiotropium 18 mcg Daily Versus Placebo DISKUS Twice Daily Plus Tiotropium 18 mcg Daily on Exercise Time and Physiological Parameters in Subjects With Chronic Obstructive Pulmonary Disease
Status: Enrolling
Updated:  10/9/2017
GSK Investigational Site
mi
from
Omaha, NE
Fluticasone Propionate/Salmeterol Combination 250/50 DISKUS in the Exercise Endurance Time in Patients With Chronic Obstructive Pulmonary Disease
A Study of Fluticasone Propionate/Salmeterol DISKUS Combination Product 250/50 mcg Twice Daily Plus Tiotropium 18 mcg Daily Versus Placebo DISKUS Twice Daily Plus Tiotropium 18 mcg Daily on Exercise Time and Physiological Parameters in Subjects With Chronic Obstructive Pulmonary Disease
Status: Enrolling
Updated: 10/9/2017
GSK Investigational Site
mi
from
Omaha, NE
Click here to add this to my saved trials
Fluticasone Propionate/Salmeterol Combination 250/50 DISKUS in the Exercise Endurance Time in Patients With Chronic Obstructive Pulmonary Disease
A Study of Fluticasone Propionate/Salmeterol DISKUS Combination Product 250/50 mcg Twice Daily Plus Tiotropium 18 mcg Daily Versus Placebo DISKUS Twice Daily Plus Tiotropium 18 mcg Daily on Exercise Time and Physiological Parameters in Subjects With Chronic Obstructive Pulmonary Disease
Status: Enrolling
Updated:  10/9/2017
GSK Investigational Site
mi
from
Lebanon, NH
Fluticasone Propionate/Salmeterol Combination 250/50 DISKUS in the Exercise Endurance Time in Patients With Chronic Obstructive Pulmonary Disease
A Study of Fluticasone Propionate/Salmeterol DISKUS Combination Product 250/50 mcg Twice Daily Plus Tiotropium 18 mcg Daily Versus Placebo DISKUS Twice Daily Plus Tiotropium 18 mcg Daily on Exercise Time and Physiological Parameters in Subjects With Chronic Obstructive Pulmonary Disease
Status: Enrolling
Updated: 10/9/2017
GSK Investigational Site
mi
from
Lebanon, NH
Click here to add this to my saved trials
Fluticasone Propionate/Salmeterol Combination 250/50 DISKUS in the Exercise Endurance Time in Patients With Chronic Obstructive Pulmonary Disease
A Study of Fluticasone Propionate/Salmeterol DISKUS Combination Product 250/50 mcg Twice Daily Plus Tiotropium 18 mcg Daily Versus Placebo DISKUS Twice Daily Plus Tiotropium 18 mcg Daily on Exercise Time and Physiological Parameters in Subjects With Chronic Obstructive Pulmonary Disease
Status: Enrolling
Updated:  10/9/2017
GSK Investigational Site
mi
from
Albany, NY
Fluticasone Propionate/Salmeterol Combination 250/50 DISKUS in the Exercise Endurance Time in Patients With Chronic Obstructive Pulmonary Disease
A Study of Fluticasone Propionate/Salmeterol DISKUS Combination Product 250/50 mcg Twice Daily Plus Tiotropium 18 mcg Daily Versus Placebo DISKUS Twice Daily Plus Tiotropium 18 mcg Daily on Exercise Time and Physiological Parameters in Subjects With Chronic Obstructive Pulmonary Disease
Status: Enrolling
Updated: 10/9/2017
GSK Investigational Site
mi
from
Albany, NY
Click here to add this to my saved trials
Fluticasone Propionate/Salmeterol Combination 250/50 DISKUS in the Exercise Endurance Time in Patients With Chronic Obstructive Pulmonary Disease
A Study of Fluticasone Propionate/Salmeterol DISKUS Combination Product 250/50 mcg Twice Daily Plus Tiotropium 18 mcg Daily Versus Placebo DISKUS Twice Daily Plus Tiotropium 18 mcg Daily on Exercise Time and Physiological Parameters in Subjects With Chronic Obstructive Pulmonary Disease
Status: Enrolling
Updated:  10/9/2017
GSK Investigational Site
mi
from
Easley, SC
Fluticasone Propionate/Salmeterol Combination 250/50 DISKUS in the Exercise Endurance Time in Patients With Chronic Obstructive Pulmonary Disease
A Study of Fluticasone Propionate/Salmeterol DISKUS Combination Product 250/50 mcg Twice Daily Plus Tiotropium 18 mcg Daily Versus Placebo DISKUS Twice Daily Plus Tiotropium 18 mcg Daily on Exercise Time and Physiological Parameters in Subjects With Chronic Obstructive Pulmonary Disease
Status: Enrolling
Updated: 10/9/2017
GSK Investigational Site
mi
from
Easley, SC
Click here to add this to my saved trials
Fluticasone Propionate/Salmeterol Combination 250/50 DISKUS in the Exercise Endurance Time in Patients With Chronic Obstructive Pulmonary Disease
A Study of Fluticasone Propionate/Salmeterol DISKUS Combination Product 250/50 mcg Twice Daily Plus Tiotropium 18 mcg Daily Versus Placebo DISKUS Twice Daily Plus Tiotropium 18 mcg Daily on Exercise Time and Physiological Parameters in Subjects With Chronic Obstructive Pulmonary Disease
Status: Enrolling
Updated:  10/9/2017
GSK Investigational Site
mi
from
Gaffney, SC
Fluticasone Propionate/Salmeterol Combination 250/50 DISKUS in the Exercise Endurance Time in Patients With Chronic Obstructive Pulmonary Disease
A Study of Fluticasone Propionate/Salmeterol DISKUS Combination Product 250/50 mcg Twice Daily Plus Tiotropium 18 mcg Daily Versus Placebo DISKUS Twice Daily Plus Tiotropium 18 mcg Daily on Exercise Time and Physiological Parameters in Subjects With Chronic Obstructive Pulmonary Disease
Status: Enrolling
Updated: 10/9/2017
GSK Investigational Site
mi
from
Gaffney, SC
Click here to add this to my saved trials
Fluticasone Propionate/Salmeterol Combination 250/50 DISKUS in the Exercise Endurance Time in Patients With Chronic Obstructive Pulmonary Disease
A Study of Fluticasone Propionate/Salmeterol DISKUS Combination Product 250/50 mcg Twice Daily Plus Tiotropium 18 mcg Daily Versus Placebo DISKUS Twice Daily Plus Tiotropium 18 mcg Daily on Exercise Time and Physiological Parameters in Subjects With Chronic Obstructive Pulmonary Disease
Status: Enrolling
Updated:  10/9/2017
GSK Investigational Site
mi
from
Greenville, SC
Fluticasone Propionate/Salmeterol Combination 250/50 DISKUS in the Exercise Endurance Time in Patients With Chronic Obstructive Pulmonary Disease
A Study of Fluticasone Propionate/Salmeterol DISKUS Combination Product 250/50 mcg Twice Daily Plus Tiotropium 18 mcg Daily Versus Placebo DISKUS Twice Daily Plus Tiotropium 18 mcg Daily on Exercise Time and Physiological Parameters in Subjects With Chronic Obstructive Pulmonary Disease
Status: Enrolling
Updated: 10/9/2017
GSK Investigational Site
mi
from
Greenville, SC
Click here to add this to my saved trials
Fluticasone Propionate/Salmeterol Combination 250/50 DISKUS in the Exercise Endurance Time in Patients With Chronic Obstructive Pulmonary Disease
A Study of Fluticasone Propionate/Salmeterol DISKUS Combination Product 250/50 mcg Twice Daily Plus Tiotropium 18 mcg Daily Versus Placebo DISKUS Twice Daily Plus Tiotropium 18 mcg Daily on Exercise Time and Physiological Parameters in Subjects With Chronic Obstructive Pulmonary Disease
Status: Enrolling
Updated:  10/9/2017
GSK Investigational Site
mi
from
Spartanburg, SC
Fluticasone Propionate/Salmeterol Combination 250/50 DISKUS in the Exercise Endurance Time in Patients With Chronic Obstructive Pulmonary Disease
A Study of Fluticasone Propionate/Salmeterol DISKUS Combination Product 250/50 mcg Twice Daily Plus Tiotropium 18 mcg Daily Versus Placebo DISKUS Twice Daily Plus Tiotropium 18 mcg Daily on Exercise Time and Physiological Parameters in Subjects With Chronic Obstructive Pulmonary Disease
Status: Enrolling
Updated: 10/9/2017
GSK Investigational Site
mi
from
Spartanburg, SC
Click here to add this to my saved trials
Fluticasone Propionate/Salmeterol Combination 250/50 DISKUS in the Exercise Endurance Time in Patients With Chronic Obstructive Pulmonary Disease
A Study of Fluticasone Propionate/Salmeterol DISKUS Combination Product 250/50 mcg Twice Daily Plus Tiotropium 18 mcg Daily Versus Placebo DISKUS Twice Daily Plus Tiotropium 18 mcg Daily on Exercise Time and Physiological Parameters in Subjects With Chronic Obstructive Pulmonary Disease
Status: Enrolling
Updated:  10/9/2017
GSK Investigational Site
mi
from
Union, SC
Fluticasone Propionate/Salmeterol Combination 250/50 DISKUS in the Exercise Endurance Time in Patients With Chronic Obstructive Pulmonary Disease
A Study of Fluticasone Propionate/Salmeterol DISKUS Combination Product 250/50 mcg Twice Daily Plus Tiotropium 18 mcg Daily Versus Placebo DISKUS Twice Daily Plus Tiotropium 18 mcg Daily on Exercise Time and Physiological Parameters in Subjects With Chronic Obstructive Pulmonary Disease
Status: Enrolling
Updated: 10/9/2017
GSK Investigational Site
mi
from
Union, SC
Click here to add this to my saved trials
Fluticasone Propionate/Salmeterol Combination 250/50 DISKUS in the Exercise Endurance Time in Patients With Chronic Obstructive Pulmonary Disease
A Study of Fluticasone Propionate/Salmeterol DISKUS Combination Product 250/50 mcg Twice Daily Plus Tiotropium 18 mcg Daily Versus Placebo DISKUS Twice Daily Plus Tiotropium 18 mcg Daily on Exercise Time and Physiological Parameters in Subjects With Chronic Obstructive Pulmonary Disease
Status: Enrolling
Updated:  10/9/2017
GSK Investigational Site
mi
from
Houston, TX
Fluticasone Propionate/Salmeterol Combination 250/50 DISKUS in the Exercise Endurance Time in Patients With Chronic Obstructive Pulmonary Disease
A Study of Fluticasone Propionate/Salmeterol DISKUS Combination Product 250/50 mcg Twice Daily Plus Tiotropium 18 mcg Daily Versus Placebo DISKUS Twice Daily Plus Tiotropium 18 mcg Daily on Exercise Time and Physiological Parameters in Subjects With Chronic Obstructive Pulmonary Disease
Status: Enrolling
Updated: 10/9/2017
GSK Investigational Site
mi
from
Houston, TX
Click here to add this to my saved trials
Fluticasone Propionate/Salmeterol Combination 250/50 DISKUS in the Exercise Endurance Time in Patients With Chronic Obstructive Pulmonary Disease
A Study of Fluticasone Propionate/Salmeterol DISKUS Combination Product 250/50 mcg Twice Daily Plus Tiotropium 18 mcg Daily Versus Placebo DISKUS Twice Daily Plus Tiotropium 18 mcg Daily on Exercise Time and Physiological Parameters in Subjects With Chronic Obstructive Pulmonary Disease
Status: Enrolling
Updated:  10/9/2017
GSK Investigational Site
mi
from
The Woodlands, TX
Fluticasone Propionate/Salmeterol Combination 250/50 DISKUS in the Exercise Endurance Time in Patients With Chronic Obstructive Pulmonary Disease
A Study of Fluticasone Propionate/Salmeterol DISKUS Combination Product 250/50 mcg Twice Daily Plus Tiotropium 18 mcg Daily Versus Placebo DISKUS Twice Daily Plus Tiotropium 18 mcg Daily on Exercise Time and Physiological Parameters in Subjects With Chronic Obstructive Pulmonary Disease
Status: Enrolling
Updated: 10/9/2017
GSK Investigational Site
mi
from
The Woodlands, TX
Click here to add this to my saved trials
Fluticasone Propionate/Salmeterol Combination 250/50 DISKUS in the Exercise Endurance Time in Patients With Chronic Obstructive Pulmonary Disease
A Study of Fluticasone Propionate/Salmeterol DISKUS Combination Product 250/50 mcg Twice Daily Plus Tiotropium 18 mcg Daily Versus Placebo DISKUS Twice Daily Plus Tiotropium 18 mcg Daily on Exercise Time and Physiological Parameters in Subjects With Chronic Obstructive Pulmonary Disease
Status: Enrolling
Updated:  10/9/2017
GSK Investigational Site
mi
from
Webster, TX
Fluticasone Propionate/Salmeterol Combination 250/50 DISKUS in the Exercise Endurance Time in Patients With Chronic Obstructive Pulmonary Disease
A Study of Fluticasone Propionate/Salmeterol DISKUS Combination Product 250/50 mcg Twice Daily Plus Tiotropium 18 mcg Daily Versus Placebo DISKUS Twice Daily Plus Tiotropium 18 mcg Daily on Exercise Time and Physiological Parameters in Subjects With Chronic Obstructive Pulmonary Disease
Status: Enrolling
Updated: 10/9/2017
GSK Investigational Site
mi
from
Webster, TX
Click here to add this to my saved trials
Fluticasone Propionate/Salmeterol Combination 250/50 DISKUS in the Exercise Endurance Time in Patients With Chronic Obstructive Pulmonary Disease
A Study of Fluticasone Propionate/Salmeterol DISKUS Combination Product 250/50 mcg Twice Daily Plus Tiotropium 18 mcg Daily Versus Placebo DISKUS Twice Daily Plus Tiotropium 18 mcg Daily on Exercise Time and Physiological Parameters in Subjects With Chronic Obstructive Pulmonary Disease
Status: Enrolling
Updated:  10/9/2017
GSK Investigational Site
mi
from
Calgary,
Fluticasone Propionate/Salmeterol Combination 250/50 DISKUS in the Exercise Endurance Time in Patients With Chronic Obstructive Pulmonary Disease
A Study of Fluticasone Propionate/Salmeterol DISKUS Combination Product 250/50 mcg Twice Daily Plus Tiotropium 18 mcg Daily Versus Placebo DISKUS Twice Daily Plus Tiotropium 18 mcg Daily on Exercise Time and Physiological Parameters in Subjects With Chronic Obstructive Pulmonary Disease
Status: Enrolling
Updated: 10/9/2017
GSK Investigational Site
mi
from
Calgary,
Click here to add this to my saved trials
A 24-week Arterial Stiffness Study With Fluticasone Furoate/Vilanterol in COPD
A 24-week Study to Evaluate the Effect of Fluticasone Furoate/Vilanterol 100/25 mcg Inhalation Powder Delivered Once-daily Via a Novel Dry Powder Inhaler on Arterial Stiffness Compared With Placebo and Vilanterol in Subjects With Chronic Obstructive Pulmonary Disease (COPD).
Status: Enrolling
Updated:  10/9/2017
GSK Investigational Site
mi
from
Birmingham, AL
A 24-week Arterial Stiffness Study With Fluticasone Furoate/Vilanterol in COPD
A 24-week Study to Evaluate the Effect of Fluticasone Furoate/Vilanterol 100/25 mcg Inhalation Powder Delivered Once-daily Via a Novel Dry Powder Inhaler on Arterial Stiffness Compared With Placebo and Vilanterol in Subjects With Chronic Obstructive Pulmonary Disease (COPD).
Status: Enrolling
Updated: 10/9/2017
GSK Investigational Site
mi
from
Birmingham, AL
Click here to add this to my saved trials
A 24-week Arterial Stiffness Study With Fluticasone Furoate/Vilanterol in COPD
A 24-week Study to Evaluate the Effect of Fluticasone Furoate/Vilanterol 100/25 mcg Inhalation Powder Delivered Once-daily Via a Novel Dry Powder Inhaler on Arterial Stiffness Compared With Placebo and Vilanterol in Subjects With Chronic Obstructive Pulmonary Disease (COPD).
Status: Enrolling
Updated:  10/9/2017
GSK Investigational Site
mi
from
Phoenix, AZ
A 24-week Arterial Stiffness Study With Fluticasone Furoate/Vilanterol in COPD
A 24-week Study to Evaluate the Effect of Fluticasone Furoate/Vilanterol 100/25 mcg Inhalation Powder Delivered Once-daily Via a Novel Dry Powder Inhaler on Arterial Stiffness Compared With Placebo and Vilanterol in Subjects With Chronic Obstructive Pulmonary Disease (COPD).
Status: Enrolling
Updated: 10/9/2017
GSK Investigational Site
mi
from
Phoenix, AZ
Click here to add this to my saved trials
A 24-week Arterial Stiffness Study With Fluticasone Furoate/Vilanterol in COPD
A 24-week Study to Evaluate the Effect of Fluticasone Furoate/Vilanterol 100/25 mcg Inhalation Powder Delivered Once-daily Via a Novel Dry Powder Inhaler on Arterial Stiffness Compared With Placebo and Vilanterol in Subjects With Chronic Obstructive Pulmonary Disease (COPD).
Status: Enrolling
Updated:  10/9/2017
GSK Investigational Site
mi
from
Newport Beach, CA
A 24-week Arterial Stiffness Study With Fluticasone Furoate/Vilanterol in COPD
A 24-week Study to Evaluate the Effect of Fluticasone Furoate/Vilanterol 100/25 mcg Inhalation Powder Delivered Once-daily Via a Novel Dry Powder Inhaler on Arterial Stiffness Compared With Placebo and Vilanterol in Subjects With Chronic Obstructive Pulmonary Disease (COPD).
Status: Enrolling
Updated: 10/9/2017
GSK Investigational Site
mi
from
Newport Beach, CA
Click here to add this to my saved trials
A 24-week Arterial Stiffness Study With Fluticasone Furoate/Vilanterol in COPD
A 24-week Study to Evaluate the Effect of Fluticasone Furoate/Vilanterol 100/25 mcg Inhalation Powder Delivered Once-daily Via a Novel Dry Powder Inhaler on Arterial Stiffness Compared With Placebo and Vilanterol in Subjects With Chronic Obstructive Pulmonary Disease (COPD).
Status: Enrolling
Updated:  10/9/2017
GSK Investigational Site
mi
from
Torrance, CA
A 24-week Arterial Stiffness Study With Fluticasone Furoate/Vilanterol in COPD
A 24-week Study to Evaluate the Effect of Fluticasone Furoate/Vilanterol 100/25 mcg Inhalation Powder Delivered Once-daily Via a Novel Dry Powder Inhaler on Arterial Stiffness Compared With Placebo and Vilanterol in Subjects With Chronic Obstructive Pulmonary Disease (COPD).
Status: Enrolling
Updated: 10/9/2017
GSK Investigational Site
mi
from
Torrance, CA
Click here to add this to my saved trials
A 24-week Arterial Stiffness Study With Fluticasone Furoate/Vilanterol in COPD
A 24-week Study to Evaluate the Effect of Fluticasone Furoate/Vilanterol 100/25 mcg Inhalation Powder Delivered Once-daily Via a Novel Dry Powder Inhaler on Arterial Stiffness Compared With Placebo and Vilanterol in Subjects With Chronic Obstructive Pulmonary Disease (COPD).
Status: Enrolling
Updated:  10/9/2017
GSK Investigational Site
mi
from
DeLand, FL
A 24-week Arterial Stiffness Study With Fluticasone Furoate/Vilanterol in COPD
A 24-week Study to Evaluate the Effect of Fluticasone Furoate/Vilanterol 100/25 mcg Inhalation Powder Delivered Once-daily Via a Novel Dry Powder Inhaler on Arterial Stiffness Compared With Placebo and Vilanterol in Subjects With Chronic Obstructive Pulmonary Disease (COPD).
Status: Enrolling
Updated: 10/9/2017
GSK Investigational Site
mi
from
DeLand, FL
Click here to add this to my saved trials
A 24-week Arterial Stiffness Study With Fluticasone Furoate/Vilanterol in COPD
A 24-week Study to Evaluate the Effect of Fluticasone Furoate/Vilanterol 100/25 mcg Inhalation Powder Delivered Once-daily Via a Novel Dry Powder Inhaler on Arterial Stiffness Compared With Placebo and Vilanterol in Subjects With Chronic Obstructive Pulmonary Disease (COPD).
Status: Enrolling
Updated:  10/9/2017
GSK Investigational Site
mi
from
Gainesville, FL
A 24-week Arterial Stiffness Study With Fluticasone Furoate/Vilanterol in COPD
A 24-week Study to Evaluate the Effect of Fluticasone Furoate/Vilanterol 100/25 mcg Inhalation Powder Delivered Once-daily Via a Novel Dry Powder Inhaler on Arterial Stiffness Compared With Placebo and Vilanterol in Subjects With Chronic Obstructive Pulmonary Disease (COPD).
Status: Enrolling
Updated: 10/9/2017
GSK Investigational Site
mi
from
Gainesville, FL
Click here to add this to my saved trials
A 24-week Arterial Stiffness Study With Fluticasone Furoate/Vilanterol in COPD
A 24-week Study to Evaluate the Effect of Fluticasone Furoate/Vilanterol 100/25 mcg Inhalation Powder Delivered Once-daily Via a Novel Dry Powder Inhaler on Arterial Stiffness Compared With Placebo and Vilanterol in Subjects With Chronic Obstructive Pulmonary Disease (COPD).
Status: Enrolling
Updated:  10/9/2017
GSK Investigational Site
mi
from
Orlando, FL
A 24-week Arterial Stiffness Study With Fluticasone Furoate/Vilanterol in COPD
A 24-week Study to Evaluate the Effect of Fluticasone Furoate/Vilanterol 100/25 mcg Inhalation Powder Delivered Once-daily Via a Novel Dry Powder Inhaler on Arterial Stiffness Compared With Placebo and Vilanterol in Subjects With Chronic Obstructive Pulmonary Disease (COPD).
Status: Enrolling
Updated: 10/9/2017
GSK Investigational Site
mi
from
Orlando, FL
Click here to add this to my saved trials
A 24-week Arterial Stiffness Study With Fluticasone Furoate/Vilanterol in COPD
A 24-week Study to Evaluate the Effect of Fluticasone Furoate/Vilanterol 100/25 mcg Inhalation Powder Delivered Once-daily Via a Novel Dry Powder Inhaler on Arterial Stiffness Compared With Placebo and Vilanterol in Subjects With Chronic Obstructive Pulmonary Disease (COPD).
Status: Enrolling
Updated:  10/9/2017
GSK Investigational Site
mi
from
Ormond Beach, FL
A 24-week Arterial Stiffness Study With Fluticasone Furoate/Vilanterol in COPD
A 24-week Study to Evaluate the Effect of Fluticasone Furoate/Vilanterol 100/25 mcg Inhalation Powder Delivered Once-daily Via a Novel Dry Powder Inhaler on Arterial Stiffness Compared With Placebo and Vilanterol in Subjects With Chronic Obstructive Pulmonary Disease (COPD).
Status: Enrolling
Updated: 10/9/2017
GSK Investigational Site
mi
from
Ormond Beach, FL
Click here to add this to my saved trials
A 24-week Arterial Stiffness Study With Fluticasone Furoate/Vilanterol in COPD
A 24-week Study to Evaluate the Effect of Fluticasone Furoate/Vilanterol 100/25 mcg Inhalation Powder Delivered Once-daily Via a Novel Dry Powder Inhaler on Arterial Stiffness Compared With Placebo and Vilanterol in Subjects With Chronic Obstructive Pulmonary Disease (COPD).
Status: Enrolling
Updated:  10/9/2017
GSK Investigational Site
mi
from
Winter Park, FL
A 24-week Arterial Stiffness Study With Fluticasone Furoate/Vilanterol in COPD
A 24-week Study to Evaluate the Effect of Fluticasone Furoate/Vilanterol 100/25 mcg Inhalation Powder Delivered Once-daily Via a Novel Dry Powder Inhaler on Arterial Stiffness Compared With Placebo and Vilanterol in Subjects With Chronic Obstructive Pulmonary Disease (COPD).
Status: Enrolling
Updated: 10/9/2017
GSK Investigational Site
mi
from
Winter Park, FL
Click here to add this to my saved trials
A 24-week Arterial Stiffness Study With Fluticasone Furoate/Vilanterol in COPD
A 24-week Study to Evaluate the Effect of Fluticasone Furoate/Vilanterol 100/25 mcg Inhalation Powder Delivered Once-daily Via a Novel Dry Powder Inhaler on Arterial Stiffness Compared With Placebo and Vilanterol in Subjects With Chronic Obstructive Pulmonary Disease (COPD).
Status: Enrolling
Updated:  10/9/2017
GSK Investigational Site
mi
from
Duluth, GA
A 24-week Arterial Stiffness Study With Fluticasone Furoate/Vilanterol in COPD
A 24-week Study to Evaluate the Effect of Fluticasone Furoate/Vilanterol 100/25 mcg Inhalation Powder Delivered Once-daily Via a Novel Dry Powder Inhaler on Arterial Stiffness Compared With Placebo and Vilanterol in Subjects With Chronic Obstructive Pulmonary Disease (COPD).
Status: Enrolling
Updated: 10/9/2017
GSK Investigational Site
mi
from
Duluth, GA
Click here to add this to my saved trials
A 24-week Arterial Stiffness Study With Fluticasone Furoate/Vilanterol in COPD
A 24-week Study to Evaluate the Effect of Fluticasone Furoate/Vilanterol 100/25 mcg Inhalation Powder Delivered Once-daily Via a Novel Dry Powder Inhaler on Arterial Stiffness Compared With Placebo and Vilanterol in Subjects With Chronic Obstructive Pulmonary Disease (COPD).
Status: Enrolling
Updated:  10/9/2017
GSK Investigational Site
mi
from
Coeur d'Alene, ID
A 24-week Arterial Stiffness Study With Fluticasone Furoate/Vilanterol in COPD
A 24-week Study to Evaluate the Effect of Fluticasone Furoate/Vilanterol 100/25 mcg Inhalation Powder Delivered Once-daily Via a Novel Dry Powder Inhaler on Arterial Stiffness Compared With Placebo and Vilanterol in Subjects With Chronic Obstructive Pulmonary Disease (COPD).
Status: Enrolling
Updated: 10/9/2017
GSK Investigational Site
mi
from
Coeur d'Alene, ID
Click here to add this to my saved trials
A 24-week Arterial Stiffness Study With Fluticasone Furoate/Vilanterol in COPD
A 24-week Study to Evaluate the Effect of Fluticasone Furoate/Vilanterol 100/25 mcg Inhalation Powder Delivered Once-daily Via a Novel Dry Powder Inhaler on Arterial Stiffness Compared With Placebo and Vilanterol in Subjects With Chronic Obstructive Pulmonary Disease (COPD).
Status: Enrolling
Updated:  10/9/2017
GSK Investigational Site
mi
from
Avon, IN
A 24-week Arterial Stiffness Study With Fluticasone Furoate/Vilanterol in COPD
A 24-week Study to Evaluate the Effect of Fluticasone Furoate/Vilanterol 100/25 mcg Inhalation Powder Delivered Once-daily Via a Novel Dry Powder Inhaler on Arterial Stiffness Compared With Placebo and Vilanterol in Subjects With Chronic Obstructive Pulmonary Disease (COPD).
Status: Enrolling
Updated: 10/9/2017
GSK Investigational Site
mi
from
Avon, IN
Click here to add this to my saved trials
A 24-week Arterial Stiffness Study With Fluticasone Furoate/Vilanterol in COPD
A 24-week Study to Evaluate the Effect of Fluticasone Furoate/Vilanterol 100/25 mcg Inhalation Powder Delivered Once-daily Via a Novel Dry Powder Inhaler on Arterial Stiffness Compared With Placebo and Vilanterol in Subjects With Chronic Obstructive Pulmonary Disease (COPD).
Status: Enrolling
Updated:  10/9/2017
GSK Investigational Site
mi
from
Lafayette, IN
A 24-week Arterial Stiffness Study With Fluticasone Furoate/Vilanterol in COPD
A 24-week Study to Evaluate the Effect of Fluticasone Furoate/Vilanterol 100/25 mcg Inhalation Powder Delivered Once-daily Via a Novel Dry Powder Inhaler on Arterial Stiffness Compared With Placebo and Vilanterol in Subjects With Chronic Obstructive Pulmonary Disease (COPD).
Status: Enrolling
Updated: 10/9/2017
GSK Investigational Site
mi
from
Lafayette, IN
Click here to add this to my saved trials
A 24-week Arterial Stiffness Study With Fluticasone Furoate/Vilanterol in COPD
A 24-week Study to Evaluate the Effect of Fluticasone Furoate/Vilanterol 100/25 mcg Inhalation Powder Delivered Once-daily Via a Novel Dry Powder Inhaler on Arterial Stiffness Compared With Placebo and Vilanterol in Subjects With Chronic Obstructive Pulmonary Disease (COPD).
Status: Enrolling
Updated:  10/9/2017
GSK Investigational Site
mi
from
Muncie, IN
A 24-week Arterial Stiffness Study With Fluticasone Furoate/Vilanterol in COPD
A 24-week Study to Evaluate the Effect of Fluticasone Furoate/Vilanterol 100/25 mcg Inhalation Powder Delivered Once-daily Via a Novel Dry Powder Inhaler on Arterial Stiffness Compared With Placebo and Vilanterol in Subjects With Chronic Obstructive Pulmonary Disease (COPD).
Status: Enrolling
Updated: 10/9/2017
GSK Investigational Site
mi
from
Muncie, IN
Click here to add this to my saved trials
A 24-week Arterial Stiffness Study With Fluticasone Furoate/Vilanterol in COPD
A 24-week Study to Evaluate the Effect of Fluticasone Furoate/Vilanterol 100/25 mcg Inhalation Powder Delivered Once-daily Via a Novel Dry Powder Inhaler on Arterial Stiffness Compared With Placebo and Vilanterol in Subjects With Chronic Obstructive Pulmonary Disease (COPD).
Status: Enrolling
Updated:  10/9/2017
GSK Investigational Site
mi
from
Topeka, KA
A 24-week Arterial Stiffness Study With Fluticasone Furoate/Vilanterol in COPD
A 24-week Study to Evaluate the Effect of Fluticasone Furoate/Vilanterol 100/25 mcg Inhalation Powder Delivered Once-daily Via a Novel Dry Powder Inhaler on Arterial Stiffness Compared With Placebo and Vilanterol in Subjects With Chronic Obstructive Pulmonary Disease (COPD).
Status: Enrolling
Updated: 10/9/2017
GSK Investigational Site
mi
from
Topeka, KA
Click here to add this to my saved trials